MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds ...

Getting to a $2 trillion market cap from Eli Lilly’s current levels would require a compound annual growth rate of about 11.7% over the next seven years. That’s no easy feat, but if Eli Lilly can pull ...

Eli Lilly's new oral weight loss drug Foundayo is under scrutiny after an FDA-reported case of liver failure and other ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the ...

Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout ...

Nearly 40% of the population in the United States develop obesity, which is linked to the development of several diseases, including type 2 diabetes ...

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...

The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...

A solitary entry in a federal adverse-event database was enough to knock nearly $15 off Eli Lilly’s share price on Monday, but the selloff proved fleeting. Within hours, the stock had clawed back into ...

New long-term data from Eli Lilly and Company show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...